Remdesivir Efficacy and Tolerability in Children with Covid-19-Associated Allergic Comorbidities such as Asthma, Allergic Rhinitis, and Atopic Dermatitis
Bibliographic Data
| ID | 15716489 |
|---|---|
| Authors | Gheorghiță Jugulete (0000-0002-4193-063X, Carol Davila University of Medicine and Pharmacy, corresponding author), Monica Luminos (Carol Davila University of Medicine and Pharmacy), Carmen Pavelescu (0000-0003-4547-3023, Carol Davila University of Medicine and Pharmacy), Mădălina Maria Merişescu (Carol Davila University of Medicine and Pharmacy) |
| Year | 2023 |
| Volume | 10 |
| Issue | 5 |
| Pages | 810-810 |
| Publication date | 2023-04-29 |
| Open Access | Yes |
| Type | ARTICLE |
| Venue | Children (JOURNAL) |
| Journal identifiers | ISSN: 2227-9067 • E-ISSN: 2227-9067 |
| Publisher | Multidisciplinary Digital Publishing Institute (PUBLISHER • CH) |
| DOI | 10.3390/children10050810 |
| PMID | 37238359 |
| OpenAlex | W4367625173 |
| Language | EN |
| Citations received | 1 |
| References cited | 35 |
In children, coronavirus disease 2019 (COVID-19) starts as a minor illness compared to adults, but during the ongoing COVID-19 pandemic, distinct SARS-CoV-2 variants and subvariants have changed options for therapies in both adults and children, especially for those with comorbidities such as allergies. On 25 April 2022, Remdesivir (RDV), a viral RNA-dependent RNA polymerase inhibitor, was approved by the Food and Drug Administration (FDA) for the treatment of pediatric patients 28 days and older, weighing ≥3 kg, hospitalized or non-hospitalized, who are at high risk of progression to severe forms of COVID-19. While RDV has been shown to have favorable effects in numerous types of research conducted on adults, such as shortening hospital stays, and has shown it has antiviral effects on various RNA viruses, there is a lack of findings regarding safety, tolerability, and efficacy of RDV in allergic pediatric patients since its initial FDA approval. This study aims to assess RDV's efficacy and tolerability in treating pediatric patients with mild and severe forms of COVID-19-associated allergies such as asthma, allergic rhinitis, and atopic dermatitis and how RDV affects the duration of hospitalization, especially for these comorbidities. The most recent pandemic wave among children rose due to the high transmissibility of the Omicron variant, and this study analyzed changes between July 2020 and September 2022 at the National Institute of Infectious Diseases "Prof. Dr. Matei Balș", Bucharest, Romania. Our retrospective study included 250 children p p p < 0.05. This article summarizes RDV's efficacy among children with COVID-19 and allergies when the clinical result was improved and reports positive effects on tolerability and reduced duration of hospitalization, especially in children with asthma, atopic dermatitis, and allergic rhinitis. More studies are needed to confirm our findings
Adverse effect · Allergy · Asthma · Atopic dermatitis · Comorbidity · Coronavirus disease 2019 (COVID-19 · Disease · Infectious disease (medical specialty · Pandemic · Tolerability · COVID-19 Clinical Research Studies · Medicine · Respiratory viral infections research · SARS-CoV-2 and COVID-19 Research · Immunology · Internal Medicine · Pediatrics
Remdesivir for the Treatment of Covid-19 — Final Report
Presenting Characteristics, Comorbidities, and Outcomes Among 5700 Patients Hospitalized With Covid-19 in the New York City Area
A pneumonia outbreak associated with a new coronavirus of probable bat origin
Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China
Clinical and Evolutionary Features of Sars-CoV-2 Infection (Covid-19) in Children, a Romanian Perspective
| Citations per year | 1 |
|---|---|
| Citation span | 2026 - 2026 (1) |
| Highly cited | No |